NVCR
- NovoCure Limited
()
Overview
Company Summary
NovoCure Limited, trading under the ticker symbol NVCR, is a global oncology company that focuses on developing and commercializing innovative therapies for cancer treatment. NovoCure's primary technology is called Tumor Treating Fields (TTFields), which applies electric fields to disrupt the division of cancer cells to slow or stop tumor growth.
TTFields is a non-invasive therapy that delivers low-intensity, alternating electric fields directly to the tumor site using a portable device. These electric fields interfere with the mitosis process, preventing cancer cells from dividing and multiplying.
NovoCure's flagship product, Optune, is an FDA-approved and CE-marked device that incorporates TTFields technology. It is used as a treatment option in glioblastoma, an aggressive form of brain cancer, both in newly diagnosed patients as well as those with recurrent disease. Optune has shown promising results in extending overall survival and progression-free survival in clinical trials.
NovoCure is continuously investing in research and development to expand the application of TTFields beyond glioblastoma. The company has ongoing clinical trials to explore the potential of TTFields in other solid tumor cancers like lung, ovarian, pancreatic, and mesothelioma.
In addition to developing innovative cancer therapies, NovoCure also focuses on improving patient outcomes by conducting extensive research, collaborating with physicians and healthcare providers, and offering support services to patients who choose to incorporate TTFields into their treatment plan.
Overall, NovoCure Limited is a company at the forefront of developing and commercializing novel cancer treatments, with the aim of improving the lives of patients worldwide by disrupting tumor growth through innovative technology.